Pediatric Melatonin ER Visits Up 530%: What Changed and What to Do

U.S. pediatric melatonin ingestions reported to poison control centers increased 530% between 2012 and 2021, becoming the most common substance reported for unintentional pediatric ingestion in 2020. The CDC's 2022 MMWR report attributed the rise to the explosion of melatonin gummies, the deregulated supply chain, and the use of melatonin as a routine sleep aid in children. Two pediatric deaths and 287 ICU admissions over the study period reframed melatonin as a substance that warrants the same household-storage seriousness as adult medication.

The Numbers

Lelak et al. analyzed 260,435 pediatric melatonin ingestions reported to U.S. poison centers from 2012 to 2021. Annual reports rose from 8,337 in 2012 to 52,563 in 2021. Children under five accounted for the majority. Of all reported cases, 27,795 required healthcare evaluation, 4,097 were hospitalized, 287 required ICU admission, and 2 children died (both with co-ingestants). The vast majority were unintentional ingestions of products kept in accessible household locations.

Why This Happened Now

Melatonin moved from niche supplement to mass-market gummy in the late 2010s. By 2022, the U.S. melatonin gummy market had grown to over $300 million annually, with much of the volume sold for children. The 2022 Cohen study in JAMA tested 25 brands of melatonin gummies and found that 22 of 25 products had melatonin content that diverged from the label by >10%. Some products contained up to 347% of the labeled dose. One product labeled as melatonin contained no melatonin and instead delivered cannabidiol (CBD).

The Dose-Response Picture

The pediatric "physiological" dose for sleep onset is 0.1–0.3 mg, the "pharmacologic" dose 1–3 mg, and "high" pediatric doses 3–5 mg. Most U.S. pediatric melatonin gummies are formulated at 1–5 mg per gummy. A 5-mg gummy is already a pharmacologic dose; a child who eats half a 60-gummy bottle has ingested 150 mg, well above any therapeutic range. Acute toxicity manifests as profound sedation, hypotension, hypothermia, GI upset, and rarely seizures.

Long-Term Use Concerns

The data on chronic melatonin use in children are limited. Concerns include theoretical effects on pubertal development (melatonin is involved in HPG axis regulation), tolerance with chronic use, and dependency on an external sleep cue rather than sleep-hygiene establishment. The American Academy of Sleep Medicine and the AAP both recommend that pediatric melatonin be used short-term and only after sleep hygiene interventions have failed, with pediatric input.

Behavioral Sleep Strategies First

For most pediatric sleep problems, behavioral interventions outperform melatonin: consistent bedtimes, removal of screens 60–90 minutes before bed, dim ambient light in the hour before sleep, age-appropriate sleep durations, treatment of underlying sleep-disordered breathing (snoring, OSA). Children with autism spectrum disorder and certain neurodevelopmental conditions have the strongest evidence base for melatonin use; healthy children with garden-variety sleep resistance do not.

Storage and Disposal

Treat melatonin gummies as a medication. Store in original container with child-resistant cap, in a locked or out-of-reach location, never in a bedside drawer or kitchen counter pillbox. Dispose of expired or unwanted product through a drug take-back program. If a child ingests an unknown quantity, call Poison Control (1-800-222-1222); most asymptomatic ingestions can be observed at home, but symptomatic children need ED evaluation.

The Regulatory Gap

In Canada, the U.K., the E.U., Australia, and Japan, melatonin is prescription-only or strictly regulated as a medication. In the U.S., it remains a dietary supplement. Multiple petitions to the FDA have requested at minimum childproof packaging, dose-labelling accuracy, and a maximum per-unit dose. As of 2026, no such regulations have been enacted.